Literature DB >> 36262689

Delayed recurrence of an iridociliary malignant melanoma 180° from the primary tumor.

Nikolas S Hopkins1, Ilyse S Kornblau1,2, Christopher E Montes-Sabino1, Alan Boom3, Matthew W Wilson1.   

Abstract

Purpose: We report the case of a 66-year-old female who returned with a rare recurrence of iridociliary melanoma 180° from the original lesion. Observations: Upon initial presentation eleven years prior, a pigmented iris lesion suspicious for primary uveal melanoma was noted in the right eye at 9 o'clock. After one year of observation, inferior growth of the iris lesion prompted treatment via primary iridectomy with excisional biopsy and pupilloplasty. Postoperative biopsy confirmed spindle B type melanoma with epithelial foci, and adjuvant brachytherapy was performed to treat the reported positive anterior ciliary body involvement. Ten years after initial plaque brachytherapy treatment, the patient returned with a pigmented iris lesion in the right eye at 3:30-5 o'clock, which was treated with enucleation. On pathology, the new melanoma was predominantly epithelioid, consistent with a transformed recurrent iridociliary melanoma. The patient remains metastasis free 13 years after initial diagnosis. Conclusions and importance: This case describes a rare, late recurrence of an iridociliary melanoma 180° away eleven years after initial presentation, emphasizing the importance of lifelong follow-up for patients with iridociliary melanoma. This rare form of recurrence has not been previously reported in the literature. We hypothesize the original lesion contained radiotherapy resistant epithelioid cells which grew superficially on the posterior iris and anterior ciliary body, ultimately breaking back through the anterior iris 180° away. Published by Elsevier Inc.

Entities:  

Keywords:  Iridociliary melanoma; Plaque brachytherapy; Recurrence

Year:  2022        PMID: 36262689      PMCID: PMC9574778          DOI: 10.1016/j.ajoc.2022.101710

Source DB:  PubMed          Journal:  Am J Ophthalmol Case Rep        ISSN: 2451-9936


  34 in total

Review 1.  Neoplastic masquerade syndromes.

Authors:  Russell W Read; Ehud Zamir; Narsing A Rao
Journal:  Surv Ophthalmol       Date:  2002 Mar-Apr       Impact factor: 6.048

2.  Surgical treatment of iris and ciliary body melanoma: follow-up of a 25-year series of patients.

Authors:  Stefan Klauber; Peter K Jensen; Jan U Prause; Svend V Kessing
Journal:  Acta Ophthalmol       Date:  2010-04-28       Impact factor: 3.761

3.  Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.

Authors:  K Gündüz; C L Shields; J A Shields; J Cater; J E Freire; L W Brady
Journal:  Arch Ophthalmol       Date:  1999-02

4.  Iris melanoma: features and prognosis in 317 children and adults.

Authors:  Carol L Shields; Swathi Kaliki; Sanket U Shah; Wenjuan Luo; Minoru Furuta; Jerry A Shields
Journal:  J AAPOS       Date:  2012-02       Impact factor: 1.220

5.  Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide.

Authors:  Carol L Shields; Swathi Kaliki; Anne Hutchinson; Stephanie Nickerson; Jinali Patel; Swarupa Kancherla; Ani Peshtani; Shazia Nakhoda; Kristen Kocher; Emily Kolbus; Emily Jacobs; Robert Garoon; Brianna Walker; Brittany Rogers; Jerry A Shields
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

6.  Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors.

Authors:  Eun-Ah Kim; Diana Salazar; Colin A McCannel; Mitchell Kamrava; David J Demanes; James Lamb; Joseph Caprioli; Tara A McCannel
Journal:  J Glaucoma       Date:  2020-01       Impact factor: 2.503

7.  Plaque radiation therapy for malignant melanoma of the iris and ciliary body.

Authors:  P T Finger
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

8.  Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes.

Authors:  Carol L Shields; Swathi Kaliki; Michael Livesey; Brianna Walker; Robert Garoon; Marissa Bucci; Eric Feinstein; Aline Pesch; Cristina Gonzalez; Sara E Lally; Arman Mashayekhi; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2013-08       Impact factor: 7.389

9.  Risk factors for ocular melanoma: Western Canada Melanoma Study.

Authors:  R P Gallagher; J M Elwood; J Rootman; J J Spinelli; G B Hill; W J Threlfall; J M Birdsell
Journal:  J Natl Cancer Inst       Date:  1985-04       Impact factor: 13.506

10.  Iris melanoma with ciliary body infiltration presenting as a presumed chronic unilateral inflammatory glaucoma. The challenges of iris tumor biopsy assessment.

Authors:  Agata Stodolska-Nowak; Wojciech Adamski; Agata Brązert; Jacek Sygut; Andrzej Marszałek; Iwona Rospond-Kubiak
Journal:  Pol J Pathol       Date:  2021       Impact factor: 1.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.